Levofloxacin (LVFX) is one of respiratory quinolones with wide spectrum of antimicrobial efficacy for Gram-positive and -negative bacteria and also atypical bacteria, and 500 mg of intravenous LVFX infusion has recently been able to use once daily based on pharmacokinetics-pharmacodynamics in Japan. So far, there had been no reports of the prospective studies evaluating efficacy and safety of LVFX in patients with nursing and healthcare-associated pneumonia (NHCAP). This study was conducted to evaluate prospectively the efficacy and safety of LVFX in patients with NHCAP categories B and C (other antibacterial agents were allowed to use with LVFX) according to Japanese guideline for NHCAP by the Japanese Respiratory Society (JRS). LVFX 500 mg was intravenously administered once daily, and the clinical efficacy and safety were evaluated by clinical symptoms, peripheral blood laboratory findings and chest X-rays. Sixty-two patients (average age was 81.2 years old, female/male was 22/40) were firstly registered and evaluated for the safety of LVFX, and eventually 54 patients were enrolled for the evaluation of clinical efficacy of LVFX. The percentage of these 54 patients aged over 65 years old was 96.3%, NHCAP category B/C was 33/21. The efficacy of LVFX in all 54 patients evaluated was 85.2% (categories B/C of NHCAP was 81.8/90.5%). In addition, the efficacies of LVFX in each pneumonia severity category by A-DROP system by JRS in NHCAP patients were 100% in mild, 86.7% in moderate, 77.8% in severe/very severe. Nine patients (2 with liver dysfunction, 6 with renal dysfunction and 1 with thrombocytopenia) out of 62 patients were reported to have possible adverse effects of LVFX. All of the patients with liver and renal dysfunctions after starting LVFX administration demonstrated mild dysfunctions and continued LVFX treatment, and these dysfunctions normalized soon after cessation of LVFX. LVFX was changed to other antibacterial agent in one patient with thrombocytopenia, and also thrombocytopenia was normalized thereafter. In conclusion, LVFX is effective and relatively safe for categories B and C in patients with NHCAP.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tazobactam/Ceftolozane (TAZ/CTLZ) and Relebactam/Imipenem (REL/IPM) susceptibility in Japan: nationwide surveillance of respiratory bacterial pathogens in 2019/20.
J Infect Chemother
December 2024
Medical Affairs, MSD K.K., Tokyo, Japan. Electronic address:
Tazobactam/ceftolozane (TAZ/CTLZ) and relebactam/imipenem/cilastatin (REL/IPM/CS) are expected to be effective for treating patients with antimicrobial-resistant infections, particularly gram-negative pathogens, but nationwide surveillance of these has not been investigated thoroughly in Japan. Pseudomonas aeruginosa (n=164), Klebsiella pneumoniae (n=141), and Haemophilus influenzae (n=156) isolated from respiratory infected patients in Japan from June 2019 through December 2020 provided by the Japanese Surveillance Committee were used. Antimicrobial susceptibility testing for TAZ/CTLZ, REL/IPM and comparator agents against isolates were carried out by broth microdilution methods according to the Clinical and Laboratory Standards Institute standard.
View Article and Find Full Text PDFInvestigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice.
J Pharm Health Care Sci
November 2024
Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-Ku, Tokyo, 105-8512, Japan.
Background: Fluoroquinolone (FQ) antimicrobials have antipyretic effects during the treatment of bacterial infections; however, it is not clear whether these are due to their antimicrobial activities or their hypothermic effects. In this study, we investigated the hypothermic effects of FQ antimicrobials (ciprofloxacin [CPFX], gatifloxacin [GFLX], and levofloxacin [LVFX]) on fever by evaluating rectal body temperature changes in a mouse model of non-bacterial fever.
Methods: CPFX, GFLX, and LVFX were administered intraperitoneally to non-bacterial fever model mice induced by yeast.
Efficacy of 1.5% levofloxacin otic solution in treating acute otitis externa: A post hoc analysis of ENT103-3001, a multicenter randomized double-blind parallel-group placebo-controlled phase III study in otitis media with persistent otorrhea.
Auris Nasus Larynx
December 2024
Department of Otorhinolaryngology, Saitama Medical University Hospital, Saitama Medical University, 38 Morohongo Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan. Electronic address:
Article Synopsis
- - The study analyzed the effectiveness of a 1.5% levofloxacin otic solution for treating acute otitis externa in patients with nonintact tympanic membranes who also had chronic and acute otitis media
- - Researchers evaluated digital endoscopic images to assess inflammatory findings and track patient improvements, comparing results between those treated with levofloxacin and a placebo group
- - Results showed that a significantly higher percentage of patients treated with levofloxacin experienced improvement in inflammatory symptoms (47.6%) and had high bacterial eradication rates (94.3%) compared to those on placebo.
Vaginal Cuff Infection Caused by After Hysterectomy for Uterine Cervical Cancer: A Case Report.
Case Rep Infect Dis
October 2024
Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Article Synopsis
- A case study highlights a rare infection caused by an endemic mycoplasma after a hysterectomy in a 29-year-old woman with cervical cancer, leading to complications like peritonitis and bowel obstruction.
- The patient's symptoms included fever, ascites, and paralytic ileus, but traditional cultures failed to identify the pathogen.
- Polymerase chain reaction (PCR) testing ultimately detected the mycoplasma, allowing for effective treatment with levofloxacin and leading to the resolution of both the infection and bowel obstruction.
Effect of the residual levofloxacin on hydroponic vegetables with sewage treatment plant tailwater: Microbial community, discharge risk and control strategy.
Ecotoxicol Environ Saf
October 2024
College of Life and Environmental Science, Wenzhou University, Wenzhou, Zhejiang 325035, PR China; State & Local Joint Engineering Research Center of Ecological Treatment Technology for Urban Water Pollution, Wenzhou, Zhejiang 325035, PR China; Key Laboratory of Zhejiang Province for Water Environment and Marine Biological Resources Protection, Wenzhou, Zhejiang 325035, PR China. Electronic address:
Article Synopsis
- Tailwater-based hydroponics can recycle domestic wastewater but the impact of residual antibiotics like Levofloxacin (LVFX) on plant growth and water quality is not fully understood.
- Experiments showed that LVFX negatively affected water spinach growth, with the best removal of LVFX occurring after 7 days of water retention, while hydroponic conditions improved microbial diversity and stability.
- When testing lettuce with actual wastewater and LVFX, activated carbon was the most effective substrate, enhancing plant growth and achieving a high removal rate of LVFX and nitrogen compounds.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!